Brief: Blueprint Medicines Announces Partial Clinical Hold For Phase 1/2 VELA Trial Of BLU-222

Blueprint Medicines

10/02/2023 13:50

Feb 10 (Reuters) - Blueprint Medicines Corp  BPMC.O :
    * BLUEPRINT MEDICINES ANNOUNCES PARTIAL CLINICAL HOLD FOR
PHASE
1/2 VELA TRIAL OF BLU-222
    * BLUEPRINT MEDICINES ANNOUNCES PARTIAL CLINICAL HOLD FOR
PHASE
1/2 VELA TRIAL OF BLU-222
    * BLUEPRINT MEDICINES CORP - PLANS TO PRESENT INITIAL DOSE
ESCALATION DATA FROM VELA TRIAL OF BLU-222 IN FIRST HALF OF 2023
    * BLUEPRINT MEDICINES - PATIENTS CURRENTLY ENROLLED IN TRIAL
ARE
CONTINUING ON STUDY DRUG AT THIS TIME
    * BLUEPRINT MEDICINES - ADDITIONAL PATIENTS WILL NOT BE
ENROLLED
UNTIL PARTIAL CLINICAL HOLD IS RESOLVED
    * BLUEPRINT MEDICINES - PLACED PARTIAL CLINICAL HOLD ON
PHASE 1/2
VELA TRIAL OF BLU-222 DUE TO VISUAL ADVERSE EVENTS OBSERVED IN
LIMITED NUMBER OF PATIENTS

Source text for Eikon:  ID:nPn40KY3Ya 
Further company coverage:  BPMC.O 
 ((Reuters.Briefs@thomsonreuters.com;))